claim
Posted by admin
•
August 28, 2026 at 06:30 AM
Insurance companies will deny coverage for daraxonrasib initially, citing cost-effectiveness thresholds, leaving patients to fight bureaucratic appeals or pay out-of-pocket.
Vote to see results
Responses & Discussion
Log in to add your response to this statement
Log InNo responses yet. Be the first to share your perspective!